Hallucinations in neurodegenerative diseases.

Area of Science:

• Neuroscience
• Neurology
• Psychiatry

Background:

• Hallucinations are common in neurodegenerative diseases, potentially serving as early diagnostic markers, particularly for Lewy Body Dementia.
• Distinguishing disease-related hallucinations from medication side effects is crucial for appropriate patient management.
• Different neurodegenerative disease types, specifically synucleinopathies and tauopathies, present distinct hallucination profiles and risk factors.

Purpose of the Study:

• To delineate the distinct characteristics and diagnostic relevance of hallucinations in synucleinopathies versus tauopathies.
• To explore the underlying mechanisms and therapeutic challenges associated with hallucinations in these conditions.
• To review current and evidence-based treatment options for hallucinations in neurodegenerative diseases.

Main Methods:

• Comparative analysis of hallucination phenomenology in synucleinopathies and tauopathies.
• Review of proposed pathogenetic mechanisms, including the 'double hit' theory.
• Examination of treatment strategies, considering drug sensitivities and empirical approaches.

Main Results:

• Synucleinopathies feature frequent, visual, short-lived hallucinations with preserved insight, potentially linked to visual and limbic/striatal dysfunction.
• Tauopathies exhibit rarer hallucinations, often within confusional states, associated with agitation and paranoia; they may exclude Parkinsonian features like progressive supranuclear palsy.
• Evidence-based treatments include clozapine and cholinesterase inhibitors for synucleinopathies, while neuroleptic sensitivity complicates Lewy Body Dementia management.

Conclusions:

• Hallucination patterns significantly differ between synucleinopathies and tauopathies, aiding in differential diagnosis.
• Targeted therapeutic strategies, including addressing visual acuity and sleep, are essential complements to empirical treatments.
• Further research into the specific mechanisms of hallucinations in different neurodegenerative diseases is warranted to improve patient outcomes.